• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

膀胱癌膀胱内灌注卡介苗后发生的全身性卡介苗病。

Systemic BCG-osis following intravesical BCG instillation for bladder carcinoma.

作者信息

Liaw Frank, Tan Yan Yu, Hendry David

机构信息

Department of Urology Queen Elizabeth University Hospital Glasgow G51 4TF UK.

Department of Gastroenterology Monklands Hospital Airdrie ML6 0JS UK.

出版信息

Clin Case Rep. 2017 Aug 15;5(10):1569-1572. doi: 10.1002/ccr3.1129. eCollection 2017 Oct.

DOI:10.1002/ccr3.1129
PMID:29026546
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5628231/
Abstract

Intravesical instillation of Bacillus Calmette-Guérin (BCG) has been shown to be an effective form of immunotherapy for bladder cancer. This case report describes a patient who develops systemic BCG-osis following intravesical BCG instillation and demonstrates the importance of being aware of more severe complications associated with BCG immunotherapy.

摘要

膀胱内灌注卡介苗（BCG）已被证明是一种有效的膀胱癌免疫治疗方式。本病例报告描述了一名患者在膀胱内灌注BCG后发生全身性BCG病，并证明了认识到与BCG免疫治疗相关的更严重并发症的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4986/5628231/dbda60ad54b5/CCR3-5-1569-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4986/5628231/5c1807dcdabc/CCR3-5-1569-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4986/5628231/dbda60ad54b5/CCR3-5-1569-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4986/5628231/5c1807dcdabc/CCR3-5-1569-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4986/5628231/dbda60ad54b5/CCR3-5-1569-g002.jpg

相似文献

1
Systemic BCG-osis following intravesical BCG instillation for bladder carcinoma.膀胱癌膀胱内灌注卡介苗后发生的全身性卡介苗病。
Clin Case Rep. 2017 Aug 15;5(10):1569-1572. doi: 10.1002/ccr3.1129. eCollection 2017 Oct.
2
Disseminated BCG sepsis following intravesical therapy for Bladder Carcinoma: A case report and review of literature.膀胱癌膀胱内灌注治疗后播散性卡介苗败血症：一例报告并文献复习
J Community Hosp Intern Med Perspect. 2020 May 21;10(2):168-170. doi: 10.1080/20009666.2020.1742475.
3
Mycobacteremia and granulomatous hepatitis following initial intravesical bacillus Calmette-Guerin instillation for bladder carcinoma.膀胱癌初次膀胱内灌注卡介苗后发生分枝杆菌血症和肉芽肿性肝炎。
Am J Gastroenterol. 1993 Jul;88(7):1112-5.
4
Urethral fistula and perineal collection during intravesical treatment for non-muscle invasive bladder cancer - A rare complication.非肌层浸润性膀胱癌膀胱内治疗期间的尿道瘘和会阴积液——一种罕见的并发症。
Urol Case Rep. 2022 Jan 17;42:102003. doi: 10.1016/j.eucr.2022.102003. eCollection 2022 May.
5
Histopathology of Disseminated Mycobacterium bovis Infection Complicating Intravesical BCG Immunotherapy for Urothelial Carcinoma.膀胱内卡介苗免疫治疗尿路上皮癌并发播散性牛分枝杆菌感染的组织病理学
Int J Surg Pathol. 2015 May;23(3):189-95. doi: 10.1177/1066896914567332. Epub 2015 Jan 22.
6
Assessing the Feasibility of Replacing Standard-Dose Bacillus Calmette-Guérin Immunotherapy with Other Intravesical Instillation Therapies in Bladder Cancer Patients: A Network Meta-Analysis.评估膀胱癌患者中用其他膀胱内灌注疗法替代标准剂量卡介苗免疫疗法的可行性：一项网状Meta分析。
Cell Physiol Biochem. 2017;41(4):1298-1312. doi: 10.1159/000464432. Epub 2017 Mar 8.
7
Prevention of the Recurrence of Superficial Bladder Cancers: Intravesical Instillation of Bacillus Calmette-guerin Versus Bacillus Calmette-guerin Plus Epirubicin.浅表性膀胱癌复发的预防：卡介苗膀胱内灌注与卡介苗加表柔比星膀胱内灌注的比较
Asian Pac J Cancer Prev. 2000;1(3):217-220.
8
Safety and Efficacy of Intravesical Bacillus Calmette-Guérin Immunotherapy in Patients with Non-Muscle-Invasive Bladder Cancer Presenting with Asymptomatic Bacteriuria: A Systematic Review.卡介苗膀胱内免疫疗法治疗无症状菌尿的非肌层浸润性膀胱癌患者的安全性和有效性：一项系统评价
Urol Int. 2017;99(1):1-5. doi: 10.1159/000477673. Epub 2017 Jun 10.
9
The fate of bacillus Calmette-Guerin after intravesical instillation.卡介苗膀胱内灌注后的转归
J Urol. 2001 May;165(5):1765-8.
10
Clinical Spectrum of Complications Induced by Intravesical Immunotherapy of Bacillus Calmette-Guérin for Bladder Cancer.卡介苗膀胱内免疫疗法治疗膀胱癌所致并发症的临床谱
J Oncol. 2019 Mar 10;2019:6230409. doi: 10.1155/2019/6230409. eCollection 2019.

引用本文的文献

1
[Intravesical instillation of bacillus Calmette-Guerin for non-muscle invasive bladder cancer: outcomes of 421 patients in a single center].卡介苗膀胱内灌注治疗非肌层浸润性膀胱癌：单中心421例患者的治疗结果
Nan Fang Yi Ke Da Xue Xue Bao. 2023 Mar 20;43(3):488-494. doi: 10.12122/j.issn.1673-4254.2023.03.21.
2
Intravesical bacillus Calmette-Guerin (BCG) in treating non-muscle invasive bladder cancer-analysis of adverse effects and effectiveness of two strains of BCG (Danish 1331 and Moscow-I).膀胱内灌注卡介苗（BCG）治疗非肌层浸润性膀胱癌——两种卡介苗菌株（丹麦1331株和莫斯科-I株）的不良反应及疗效分析
Asian J Urol. 2022 Apr;9(2):157-164. doi: 10.1016/j.ajur.2021.05.002. Epub 2021 May 18.
3

本文引用的文献

1
Does the Compliance to Intravesical BCG Differ between Common Clinical Practice and International Multicentric Trials?普通临床实践与国际多中心试验中膀胱内卡介苗灌注的依从性是否存在差异？
Urol Int. 2016;96(1):20-4. doi: 10.1159/000430501. Epub 2015 Jul 17.
2
Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature.卡介苗（BCG）膀胱内灌注作为膀胱癌辅助治疗后的感染：单中心系列研究中的发病率、危险因素及结局，并对文献进行综述
Medicine (Baltimore). 2014 Oct;93(17):236-254. doi: 10.1097/MD.0000000000000119.
3
Mycobacterium bovis bacille Calmette-Guerin-derived extracellular vesicles as an alternative to live BCG immunotherapy.
牛分枝杆菌卡介苗衍生的细胞外囊泡作为活卡介苗免疫治疗的替代物。
Clin Exp Med. 2023 Jun;23(2):519-527. doi: 10.1007/s10238-022-00794-4. Epub 2022 Jan 25.
4
Testicular tuberculosis: An uncommon complication after treatment of urothelial carcinoma.睾丸结核：尿路上皮癌治疗后的一种罕见并发症。
Radiol Case Rep. 2020 Sep 11;15(11):2285-2293. doi: 10.1016/j.radcr.2020.07.030. eCollection 2020 Nov.
5
Disseminated BCG sepsis following intravesical therapy for Bladder Carcinoma: A case report and review of literature.膀胱癌膀胱内灌注治疗后播散性卡介苗败血症：一例报告并文献复习
J Community Hosp Intern Med Perspect. 2020 May 21;10(2):168-170. doi: 10.1080/20009666.2020.1742475.
6
Synthesis, characterization, and biological activity of a triphenylphosphonium-containing imidazolium salt against select bladder cancer cell lines.三苯基膦含咪唑鎓盐的合成、表征及对选择性膀胱癌细胞系的生物活性。
Eur J Med Chem. 2020 Jan 1;185:111832. doi: 10.1016/j.ejmech.2019.111832. Epub 2019 Oct 31.
7
Clinical Spectrum of Complications Induced by Intravesical Immunotherapy of Bacillus Calmette-Guérin for Bladder Cancer.卡介苗膀胱内免疫疗法治疗膀胱癌所致并发症的临床谱
J Oncol. 2019 Mar 10;2019:6230409. doi: 10.1155/2019/6230409. eCollection 2019.
Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.
卡介苗免疫疗法治疗泌尿生殖系统癌症。
BJU Int. 2013 Aug;112(3):288-97. doi: 10.1111/j.1464-410X.2012.11754.x. Epub 2013 Mar 20.
4
Systemic granulomatous reaction secondary to treatment of bladder cancer with bacillus calmette-guerin.卡介苗治疗膀胱癌后全身肉芽肿反应。
Mediterr J Hematol Infect Dis. 2012;4(1):e2012040. doi: 10.4084/MJHID.2012.040. Epub 2012 Jun 18.
5
Intravesical therapy for urothelial carcinoma of the bladder.膀胱尿路上皮癌的膀胱内治疗
Indian J Urol. 2011 Apr;27(2):252-61. doi: 10.4103/0970-1591.82846.
6
Isoniazid resistance among Bacillus Calmette Guerin strains: implications on bladder cancer immunotherapy related infections.卡介苗菌株中的异烟肼耐药性：对膀胱癌免疫治疗相关感染的影响。
Can J Urol. 2011 Jun;18(3):5671-5.
7
Novel insights into the mechanism of action of intravesical immunomodulators.对膀胱内免疫调节剂作用机制的新见解。
In Vivo. 2005 May-Jun;19(3):611-21.
8
Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials.卡介苗膀胱灌注在降低高危浅表性膀胱癌肿瘤复发方面优于丝裂霉素C：一项随机试验的荟萃分析
BJU Int. 2004 Mar;93(4):485-90. doi: 10.1111/j.1464-410x.2003.04655.x.
9
Spectrum of bacille Calmette-Guérin (BCG) infection after intravesical BCG immunotherapy.膀胱内卡介苗免疫治疗后卡介苗（BCG）感染谱
Clin Infect Dis. 2003 Jan 15;36(2):140-8. doi: 10.1086/344908. Epub 2003 Jan 3.
10
Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials.膀胱内灌注卡介苗可降低浅表性膀胱癌患者的疾病进展风险：一项对已发表的随机临床试验结果的荟萃分析。
J Urol. 2002 Nov;168(5):1964-70. doi: 10.1016/S0022-5347(05)64273-5.